OBJECTIVE This study investigated the efficacy and safety of multiple exenatide once-monthly suspension (q.m.s.) doses of exenatide-containing microspheres in Miglyol referenced against the clinical dose of exenatide once-weekly (q.w.) microspheres in aqueous solution.
RESEARCH DESIGN AND METHODS In this phase 2, randomized, controlled, single-blind study, 121 adults (∼30/arm) with type 2 diabetes and HbA1c 7.1–11.0% (54–97 mmol/mol) were randomized 1:1:1:1 to subcutaneous exenatide 2 mg q.w. (self-administered) or exenatide 5, 8, or 11 mg q.m.s. (caregiver-administered) for 20 weeks. The primary end point was change in HbA1c.
RESULTS At baseline, mean age was 50 years, HbA1c was 8.5% (69 mmol/mol), fasting plasma glucose (FPG) was 184 mg/dL, and body weight was 98 kg. At week 20, mean ± SD HbA1c reductions were −1.54% ± 1.26% with exenatide once weekly and −1.29% ± 1.07%, −1.31% ± 1.66%, and −1.45% ± 0.93% with exenatide 5, 8, and 11 mg q.m.s., respectively (evaluable population: n = 110). There were no significant differences in HbA1c reductions among the exenatide once-monthly suspension doses. FPG reductions were −34 ± 48 mg/dL with exenatide once weekly and −25 ± 43, −30 ± 52, and −49 ± 49 mg/dL with exenatide 5, 8, and 11 mg q.m.s., respectively. Weight decreased with all treatments. For exenatide once-monthly suspension, nausea (16.7–23.3%) and headache (16.7–26.7%) were the most common adverse events. No major or minor hypoglycemia occurred.
CONCLUSIONS All doses of exenatide once-monthly suspension resulted in efficacy and tolerability profiles consistent with exenatide once weekly. These results combined with pharmacokinetic and pharmacodynamic modeling could inform dose selection for further development.
- Received February 3, 2016.
- Accepted July 4, 2016.
- © 2016 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered.